THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 在手术中和手术后，进行静脉输液治疗以弥补血液和液体的损失是一种标准的程序。通常给出的液体是基于盐水的溶液。这些溶液分布在人体的血液和组织中。我们认为某些药物(β-肾上腺素能药)会影响静脉液体疗法的分布。这个项目的具体目标是找出是什么使液体从血液中流出进入组织，以及药物(β-肾上腺素能药物)可能如何影响这一点。我们建议在人体上测试在短时间内给予静脉输液的影响。我们想知道有多少液体留在血液中，有多少液体进入组织。为了进行这项研究，需要对腿部进行一系列的血液样本和测量。这项研究的一部分是研究流体在正常状态下的分布情况。这项研究的另一个部分是观察当患者服用被称为β-受体阻滞剂的药物时，体液分布是否发生变化。出于安全和科学原因，我们将在整个研究期间测量生命体征。我们将招收48名年龄在18岁至50岁之间的健康人。这些研究的重要性将使医生1)更好地了解液体治疗，2)关于某些药物如何影响液体治疗的信息，3)可能减少疾病和死亡的更好的液体治疗计划。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. During and after surgery it is a standard procedure to administer intravenous fluid therapy to replace blood and fluid losses. Fluids normally given are saline-based solutions. These solutions distribute into the blood and tissues of the body. We suggest that certain medicines (beta-adrenergic agents) affect the distribution of intravenous fluid therapy. The specific aims of this project are to find out what makes fluid to move out from the blood into the tissues and how medicines (beta-adrenergic agents) may affect this. We propose to test, in people, the affect of giving intravenous fluid given over a short period of time. We want to know how much of the fluid stays in the blood and how much fluid goes into the tissues. In order to do this study, a series of blood samples and measurements are needed from the leg. One part of this study is to study how fluids distribute in a normal state. Another part of this study is to see if distribution of fluid changes when patients are given medications called beta-blockers. We will measure vital signs throughout the study period for safety and for scientific reasons. We will enroll 48 healthy people between the ages of 18 and 50 years. The importance of these studies will give doctors 1) a better understanding of fluid therapy 2) information about how certain medicines impact fluid therapy 3) a better fluid therapy plan that may decrease illness and death.